Immix Biopharma (IMMX) Cash & Equivalents (2020 - 2026)

Immix Biopharma has disclosed Cash & Equivalents across 7 years of filings, most recently posting $79.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $79.3 million, up 397.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $79.3 million (up 397.77% YoY), and the FY2025 annual result was $93.9 million, up 431.21% from the prior year.
• Cash & Equivalents came in at $79.3 million for Q1 2026 at Immix Biopharma, down from $93.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $93.9 million in Q4 2025 to a low of $11.5 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $18.0 million (2022), against an average of $26.4 million.
• Peak annual rise in Cash & Equivalents reached 431.21% in 2025, while the deepest fall reached 51.62% in 2025.
• Immix Biopharma's Cash & Equivalents stood at $16.9 million in 2022, then rose by 3.51% to $17.5 million in 2023, then grew by 0.98% to $17.7 million in 2024, then surged by 431.21% to $93.9 million in 2025, then slipped by 15.63% to $79.3 million in 2026.
• The last three Cash & Equivalents figures came in at $79.3 million (Q1 2026), $93.9 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.